Janus Henderson Group PLC Has $7.03 Million Stock Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Janus Henderson Group PLC grew its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 28.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 189,347 shares of the company's stock after purchasing an additional 42,302 shares during the quarter. Janus Henderson Group PLC owned about 0.39% of Amphastar Pharmaceuticals worth $7,030,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in AMPH. Pacer Advisors Inc. grew its position in shares of Amphastar Pharmaceuticals by 51,977.4% during the 4th quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company's stock worth $50,139,000 after buying an additional 1,347,775 shares during the period. Boston Trust Walden Corp boosted its stake in Amphastar Pharmaceuticals by 81.4% during the 4th quarter. Boston Trust Walden Corp now owns 978,920 shares of the company's stock worth $36,347,000 after acquiring an additional 439,281 shares during the last quarter. Boston Partners acquired a new position in Amphastar Pharmaceuticals during the fourth quarter valued at approximately $15,778,000. Wealthfront Advisers LLC bought a new stake in Amphastar Pharmaceuticals in the fourth quarter valued at approximately $9,268,000. Finally, Dimensional Fund Advisors LP increased its stake in Amphastar Pharmaceuticals by 9.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,198,590 shares of the company's stock valued at $44,503,000 after purchasing an additional 105,288 shares in the last quarter. 65.09% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on AMPH shares. JPMorgan Chase & Co. reissued a "neutral" rating and set a $30.00 price target (down from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Piper Sandler reduced their target price on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a report on Friday, March 21st. Wells Fargo & Company decreased their target price on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a research note on Thursday, May 8th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, April 10th. Four analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $32.33.

Amphastar Pharmaceuticals Stock Up 1.1%

Shares of NASDAQ:AMPH traded up $0.28 during midday trading on Tuesday, reaching $25.07. 482,087 shares of the company were exchanged, compared to its average volume of 478,478. The firm has a market cap of $1.19 billion, a PE ratio of 8.36, a P/E/G ratio of 2.19 and a beta of 0.78. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $22.64 and a fifty-two week high of $53.96. The stock has a fifty day simple moving average of $25.38 and a two-hundred day simple moving average of $33.48. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of Amphastar Pharmaceuticals stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total value of $116,521.74. Following the sale, the chief financial officer now directly owns 97,363 shares in the company, valued at approximately $2,681,377.02. The trade was a 4.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders have sold 5,231 shares of company stock worth $142,752. Corporate insiders own 27.50% of the company's stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.